INNOVATE (NYSE:VATE) Announces Quarterly Earnings Results

Key Points

• INNOVATE beat quarterly expectations, reporting $1.10 per share versus the consensus estimate of a $2.18 loss, and revenue of $495.5 million versus expectations of $251.7 million. Revenue and adjusted EBITDA rose year over year, primarily on stronger infrastructure results.
• After quarter-end, INNOVATE sold DBM Global for approximately $413 million in cash and used proceeds to repay its credit line and redeem $325 million of notes, reducing principal indebtedness from $583.3 million to $238.3 million.
• Life sciences remains a challenge: revenue fell 61.3% year over year to $1.2 million, and R2 has yet to convert substantial reported demand into sales. Management cited manufacturing expansion, but acknowledged execution is still needed.

INNOVATE (NYSE:VATE - Get Free Report) announced its earnings results on Thursday. The company reported $1.10 earnings per share for the quarter, topping the consensus estimate of ($2.18) by $3.28, FiscalAI reports. The company had revenue of $495.50 million for the quarter, compared to analysts' expectations of $251.70 million.

Here are the key takeaways from INNOVATE's conference call:

• INNOVATE reported third-quarter revenue of $495.5 million and adjusted EBITDA of $40.5 million, up from $347.1 million and $19.8 million a year earlier; net income attributable to common and participating preferred stockholders was $15.8 million. The improvement was driven primarily by infrastructure, especially DBM Global, whose results benefited from higher activity and project efficiencies.
• The company completed the sale of DBM Global after quarter-end, receiving approximately $413 million in cash and retaining an ownership interest in IES Holdings; it also sold a controlling interest in broadcasting while keeping a 25% stake and an option to increase it. INNOVATE said it used DBM sale proceeds to repay its corporate credit line and redeem $325 million of senior secured notes, reducing principal indebtedness from $583.3 million to $238.3 million.
• MediBeacon reported progress toward broader adoption of its TGFR System, reimbursement initiatives, and U.S. validation studies for a wireless sensor; it also secured orders for 600 monitors in China, with shipments planned from late 2026 through the second quarter of 2027. Management cautioned that conversion of commercial interest may take six to 12 months, and initial pharmaceutical clinical-trial use is anticipated in 2027.
• R2 cited worldwide demand of 3.1 million, but recognized only $1.2 million in quarterly revenue, and life sciences revenue overall fell 61.3% year over year to $1.2 million. R2 said manufacturing is expanding, with 116 systems carried into the fourth quarter representing roughly $1.9 million of potential future revenue, but converting demand into sales remains a key execution challenge.

INNOVATE Trading Down 8.2%

INNOVATE stock traded down $0.43 during midday trading on Thursday, reaching $4.84. 68,202 shares of the stock traded hands, compared to its average volume of 150,304. The company has a 50-day simple moving average of $6.64 and a two-hundred day simple moving average of $8.86. INNOVATE has a 12-month low of $3.75 and a 12-month high of $21.30. The firm has a market cap of $65.97 million, a PE ratio of -2.59 and a beta of 2.57.

Analysts Set New Price Targets

VATE has been the topic of several recent analyst reports. Wall Street Zen lowered shares of INNOVATE from a "strong-buy" rating to a "buy" rating in a report on Saturday, September 12th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of INNOVATE in a research report on Wednesday. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company has a consensus rating of "Sell".

About INNOVATE

INNOVATE Corp. NYSE: VATE is a diversified holding company focused primarily on infrastructure and life sciences businesses. Through its subsidiaries, the company operates businesses involved in structural steel fabrication, industrial construction, engineering and related infrastructure services, as well as the development and commercialization of medical technologies. Its infrastructure operations are centered on DBM Global, a provider of structural steel and related services for commercial, industrial, institutional and infrastructure projects.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.